Madrigal Pharma (MDGL) CFO on Runaway Growth in Liver Disease Treatment
Description
Mardi Dier, CFO of Madrigal Pharmaceuticals (MDGL), spotlights their latest quarter and the launch of their first product. Their drug treats liver disease (specifically MASH), and she says they are already on track for $1 billion in sales. Mardi also highlights their strong balance sheet, international expansion, and an extended patent. She stresses that there are millions of patients living with MASH, and there are few other therapies in the field.
======== Schwab Network ========
Empowering every investor and trader, every market day.
Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe
Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185
Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7
Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch
Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore
Watch on DistroTV - https://www.distro.tv/live/schwab-network/
Follow us on X – https://twitter.com/schwabnetwork
Follow us on Facebook – https://www.facebook.com/schwabnetwork
Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/
About Schwab Network - https://schwabnetwork.com/about























